|Other names||AA-560; N-(2-Chloromethyl-2-hydroxypropionyl)-3,4,5-trichloroaniline|
|Drug class||Nonsteroidal antiandrogen|
|Chemical and physical data|
|Molar mass||282.55 g·mol−1|
|3D model (JSmol)|
AA560 is an orally active nonsteroidal antiandrogen (NSAA) that was developed in Japan and was first described in the literature in 1977 but was never marketed. It is an anilide derivative and analogue of the NSAA flutamide, and shows greater in vivo antiandrogenic potency than does flutamide. Similarly to flutamide, AA560 is a selective antagonist of the androgen receptor (AR) and consequently shows progonadotropic effects by increasing levels of gonadotropins and testosterone via disinhibition of the hypothalamic-pituitary-gonadal axis.
- Shida, Keizo; Yamanaka, Hidetoshi; Koya, Atsushi; Wakabayashi, Katsumi; Mori, Hiroshi; Shibata, Kenyu; Shimazawa, Eiichiro (1980). "Action of a novel nonsteroidal antiandrogen, AA560". Endocrinologia Japonica. 27 (1): 69–76. doi:10.1507/endocrj1954.27.69. ISSN 0013-7219.
- Yamanaka, Hidetoshi; Koya, Atsushi; Imai, Kyoichi; Nakai, Katsuyuki; Yuasa, Hisako; Sugiyama, Yuko; Shida, Keizo; Wakabayashi, Katsumi (1981). "Effect of AA560 (a nonsteroidal antiandrogen) implantation in the hypothalamus on gonadotropin secretion in male rats". Endocrinologia Japonica. 28 (6): 819–822. doi:10.1507/endocrj1954.28.819. ISSN 0013-7219.
- Singh SM, Gauthier S, Labrie F (2000). "Androgen receptor antagonists (antiandrogens): structure-activity relationships". Curr. Med. Chem. 7 (2): 211–47. doi:10.2174/0929867003375371. PMID 10637363.
- Annual Reports in Medicinal Chemistry. Academic Press. 16 September 1986. pp. 181–. ISBN 978-0-08-058365-5.
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|